Skip to content

Curative effect observation of symptoms and emotions, which Electric acupuncture auxiliary rabeprazole treats NERD: a multicenter, parallel,single blind, three-arm, randomized controlled trial

"Evaluation of an optimized treatment combining 'Tongduigui Qi' acupuncture method and drug therapy for non-erosive reflux disease (NERD) and exploration of its mechanisms."

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026001130
Enrollment
Unknown
Registered
2026-04-30
Start date
2025-01-03
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NERD

Interventions

Experimental group: Tongdu Leading Qi Method acupuncture combined with Western medicine oral administration, Tongdu Leading Qi Method acupuncture.:Acupuncture intervention:Needles used: 40 mm long, 0.

Sponsors

Nanjing Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria (1) Typical symptoms of gastroesophageal reflux disease, such as heartburn and regurgitation, have been present for more than 4 weeks. 2) Endoscopy results are negative, with no evidence of Barrett's esophagus, esophageal mucosal lesions, or other diseases. 3) Proton pump inhibitor (PPI) challenge test is positive); 2. Age 18–70 years; Open to all genders; 3. No use of proton pump inhibitor (PPI) medications within the past month; 4. Signed informed consent form. 3. No use of proton pump inhibitor (PPI) medications within the past month. 4. Signed informed consent form.

Exclusion criteria

Exclusion criteria: 1. Those with recent symptoms such as dysphagia, melena, or weight loss (or suspected to have peptic ulcers or malignant tumors); 2. Those with physical examination findings of rebound tenderness, abdominal masses, or other abnormalities; those with a history of gastric surgery; 3. Those with severe cardiovascular or pulmonary diseases, abnormal liver or kidney function, diabetes, acquired immunodeficiency syndrome, hemophilia, or a tendency to bleed; 4. Those unable to undergo gastroscopy, high-resolution esophageal manometry, or multi-channel 24-hour esophageal pH-impedance monitoring; 5. Those who have developed allergies or adverse reactions to the investigational drug; 6. Pregnant or breastfeeding women; 7. Those with mental disorders or unable to cooperate; 8. Those who have participated in other clinical trials recently.

Design outcomes

Primary

MeasureTime frame
Reflux Disease Diagnostic Questionnaire;

Secondary

MeasureTime frame
Anxiety Self-Rating Scale;Self-Rating Depression Scale;

Countries

China

Contacts

Public ContactZhaoming Chen

Nanjing Hospital of Traditional Chinese Medicine

czm6704@163.com15380881209

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Jun 11, 2026